Author: Paul Eftang, President and CEO of Nootropics Depot
June 19th, 2026
An athlete-focused examination of electrolyte design, mineral form selection, and comprehensive hydration support.
Click here to download the White Paper
Beyond The Marker: A Bioactives-First Standard for Reishi Quality
White Paper · Reishi Quality Standardization
Beyond The Marker:
A Bioactives-First Standard
for Reishi Quality
A practical proposal for defining Reishi bioactive STAGs (Standardized Target Analyte Groupings) and testing them across fruiting body, mycelium, and spore products. Written for consumers, brands, manufacturers, analytical labs, and scientists who want Reishi quality claims that map to compounds the body can actually use. Includes example assay data from Omnient Labs.
Bioactives · STAGs · Practical Testing
Executive Summary
What Reishi Quality Should Mean
Reishi (Ganoderma lucidum) is one of the most chemically rich medicinal mushrooms in commerce. The fruiting body, the mycelium, and the spores each carry their own distinct chemistry, and together they contain hundreds of compounds with documented biological activity: ganoderic acids, ganoderenic acids, lucidenic acids, triterpenoid alcohols, beta-glucans, sterols, nucleosides, and meroterpenoids, among others.1
Quality testing in the Reishi market has not kept up with that chemistry. Most certificates of analysis report a single ganoderic acid number, or a colorimetric "total polysaccharide" figure that cannot tell starch from beta-glucan. The result is a market where two products with the same printed number can carry very different chemistry inside the bottle.
Two laboratories testing the same extract can produce wildly different numbers, because the underlying methodologies, methods, and compounds being tested are not the same. When Nootropics Depot purchased and tested the same products that had been reported as high in ganoderic acids by a Consumer Lab a few years ago, our validated UPLC-DAD method found orders of magnitude less than CL had published. In some cases they were below our limit of detection. This kind of discrepancy is consistent with the use of generic "total triterpene" UV methods, which can overstate lanostane content by counting non-specific terpenes. After other investigations, we have also encountered labs issuing certificates without traceable raw data, COAs not supported by underlying chromatographic data, or without any data at all. This practice of "dry labbing" has become more common in recent years. This is not only a problem for consumers who think they are getting quality Reishi when they are not; it is a legal and regulatory risk for the brands themselves. Buyers, formulators, and consumers need to be using the same ruler to measure the quality of these Reishi products.
Thesis: If Reishi is standardized because it is supposed to have an intended effect in the people that consume it, then the compounds chosen for standardization should be bioactives tied to plausible mechanisms, not generic markers picked for analytical convenience. Also, every grouped claim, such as "total ganoderic acids," should declare exactly which compounds it counts. We call that declared list a STAG, a Standardized Target Analyte Grouping. By using STAG to define the analytes in a standardization, it provides clarity to labs, brands, and consumers as to what is being measured.
What this paper proposes: a bioactives-first standard, a STAG concept that makes any total claim verifiable, and four practical lab method profiles for fruiting body, mycelium, and spore products. Written for consumers, brands, manufacturers, and labs.
Problem with Current Standardization
A Generic Marker Is Not a Bioactive
Almost every Reishi specification in commerce relies on one or both of two analytical shortcuts:
Shortcut one, an invalid total triterpene or ganoderic acid number. Pharmacopoeial monographs typically anchor on ganoderic acid A, or a small handful of analytes, and call the result a triterpene total. The peaks might be real, but represent a fraction of the lanostane chemistry an authentic fruiting body can contain. Lucidenic acids, ganoderenic acids, lanostane alcohols, and the Greek-letter ganoderic acids that dominate spore preparations are not in the integrated list. In many cases simple terpene assays are used to get a total, and brands then claim that number as total ganoderic acids when all that was measured was generic terpenes. The methodology is ripe for adulteration, like with ursolic acid spiking.
Shortcut two, a colorimetric polysaccharide figure. Phenol-sulfuric and anthrone reactions read sugar, not linkage. Beta-(1,3/1,6)-D-glucan, the immunomodulating polysaccharide the Reishi literature points to, gives the same color as alpha-D-glucan (starch). A myceliated grain product can therefore report a high "total polysaccharide" value on the strength of its grain residue alone. Megazyme beta-glucan kits help bridge the gap, but have methodological limits that still need solving.
| Reference | Polysaccharide minimum | Triterpene minimum | What the test cannot resolve |
|---|---|---|---|
| Chinese Pharmacopoeia (2020) | ≥ 0.90% as glucose | ≥ 0.50% as oleanolic acid | Beta vs alpha glucan; the rest of the lanostane panel |
| USP | ≥ 0.7% | ≥ 0.3% Ganoderic acid A | Lucidenic acids; alcohols; spore-enriched congeners |
| Common industry COA practice | Single colorimetric figure | Single GA-A peak or unspecified "total" | Identity of the integrated peaks; substrate dilution |
A label that says "total ganoderic acids 4%" can mean four different things, depending on which compounds the lab counted and how. Two products with the same printed number can differ in real chemistry by orders of magnitude. The fix is not a simplified STAG; it is a more comprehensive list of bioactives, with the compounds counted in the total spelled out on the certificate.
Figure · Marker vs Bioactive: Where Chemistry-Convenient Picks Fall Short
Marker Route
Chitin in cell wall
What it tells you: Identity · fungal biomass clue
Mechanism?
No bioactive effect to point to
Bioactive STAG
GA / GE acids · lucidenic acids
To Mechanism
NF-κB · ACE2 · hepatoprotection
Quality Claim
Tied to consumer-relevant biology
Bioactives-First Thesis
Standardize to the Compounds That Matter
A bioactive is a compound (or a structurally defined class) with documented or plausible biological activity that is relevant to the reason a consumer is taking the product. A biomarker, in the way the term is often used in industry, is a compound that is convenient to measure and reasonably specific to the species. The two are not the same thing. A compound can be an analytically convenient biomarker (clean peak, specific to Ganoderma) and a poor bioactive (no documented mechanism, low biological relevance). And a compound with important biological activity can be difficult to analytically integrate (poor chromophore, co-elution with other peaks, no reference standard).
Standardize To
Ganoderic and ganoderenic acids
Triterpene Chemistry
Lanostane skeleton · oxygenation pattern
Plausible Mechanism
NF-κB · hepatoprotection · antitumor signal
Quality Claim
With meaning to the consumer
Figure · The Bioactives-First Chain from Standard to Claim
When standardization optimizes for analytical convenience, the biology drops out of the conversation. The product on the shelf is a different product than the literature describes. A real-world example of this is the current controversy around withanolide testing in ashwagandha. The USP monograph was set around measuring a very limited set of withanolides found only in the root. It measures 8 total withanolides, but there are over 40 in ashwagandha, so it misses a lot of the biological picture.19 It has also been misused to test products containing leaf, which is outside of its intended use, giving inaccurate results.20,21 This is why we need to take standardization to a broad set of bioactives seriously.
Practical Implication: Method scope should follow biology. Pick the compounds first, on the basis of their plausible or documented activity. Then design the method around quantifying them. Specificity for the ingredient comes from the panel as a whole, not from collapsing the matrix to one peak. Where the chemistry is unavoidably split (chromophore-rich acids vs weakly UV-absorbing alcohols vs polysaccharides), the panel is split too. That is how the chemistry already behaves; the method should match it.
This paper proposes three things, in order. First, a short, defensible list of Reishi bioactive classes worth standardizing to, with the evidence behind each. Second, a labeling discipline (the STAG concept) that makes any "total" claim verifiable across labs and across COAs. Third, four practical lab method profiles: one for the chromophore-rich acid set, one for the alcohol set, one for mycelium and full-spectrum products, and one for spore products. These are not new instruments. They are existing methods, scoped honestly.
Where This Fits in the Wider Conversation
AOAC INTERNATIONAL launched its Botanical Ingredients and Dietary Supplement Integrity (BIDSI) program in 2023, and has issued a public call for participants in a Reishi working group to develop performance requirements and official methods.12,13 The proposal in this paper may inform that discussion. It is also useful as is, today, for any brand or lab choosing how to specify Reishi.
Bioactive Classes
Ganoderma Contains 5 Primary Bioactive Classes
Reishi triterpenoids are lanostane-type tetracyclic terpenes built from lanosterol via the mevalonate pathway. The C30 (and C27 nor-) skeletons split into chemically distinct sub-classes that behave differently in chromatography, ionize differently in mass spectrometry, and contribute differently to the reported activity profile. Treating them as a single "triterpene fraction" is convenient and discards information the consumer is paying for.1
Type I Ganoderic Acids
Single double bond on the tetracyclic ring system. The majority of the GA pool in G. lucidum fruiting body. UV-active around 252 to 257 nm; the classic targets for HPLC-DAD work (GA-A, B, C1, C2, D, F, G, H, J series). Appropriate for the acidic-triterpene STAG, due to the chromophore present.
Type II Ganoderic Acids
Conjugated double bonds (C7=C8, C9=C11) from a cationic cascade. Often stronger antitumor activity than Type I. Distinct UV signature; spore preparations are enriched. Useful for spore panels and for telling wood-log cultivation apart from substitute cultivation.
Ganoderic acid A (Type I example)
C₃₀H₄₄O₇ · 516.67 g/mol
PubChem CID 471002
Ganoderic acid DM (Type II example)
Type II ganoderic acid · conjugated Δ-7,9(11) diene
PubChem CID 11784642
All ganoderic acids share the lanostane skeleton; lucidenic acids are the C27 (25,26,27-trinorlanostane) analogues, carboxyl at C-24. Twenty-two lucidenic acids are documented; several have activity profiles (ACE2, AChE / PTP1B, anti-viral) that ganoderic acids do not duplicate.2 Apart from the ganoderic and lucidenic acids, there are four further classes of bioactives in Reishi worth investigating: beta-glucan polysaccharides (linkage-resolved), sterols, nucleosides, and meroterpenoids.3
| Class | Representative compounds | Primary mechanism / role | Method family |
|---|---|---|---|
| I. Core Ganoderic/Ganoderenic Acids | GA-A, B, C1, C2, C6, D, F, G, H, J, T; ganoderenic A–H; α, β, γ, ε (spore) | NF-κB, MMP-9, hepatoprotection, antitumor | HPLC-DAD 252 to 257 nm; UPLC-MS/MS |
| II. Lucidenic acids (C27) | LA-A, B, C, D2, E2, N, O, Q | ACE2 blockade, AChE/PTP1B inhibition, anti-viral | HPLC-DAD; UPLC-MS/MS confirmation |
| III. Polysaccharides | β-(1,3/1,6)-D-glucan, heteroglucans | TLR2 / Dectin-1 immunomodulation | Enzymatic (Megazyme); GC-MS; NMR |
| IV. Sterols | Ergosterol, ergosterol peroxide, lanosterol | Provitamin D2; HepG2 antitumor; pathway anchor | HPLC-UV 280 nm |
| V. Nucleosides | Adenosine, uridine, inosine, guanosine | Anti-platelet, lipid-lowering, neuroprotective | HPLC-UV 254 nm |
| VI. Meroterpenoids; FIPs | Lingzhiol, ganomycins, chizhines, applanatumins; Ling Zhi-8 | Renoprotection, JAK3, HMG-CoA, COX-1/2; lectin immunostimulation | UPLC-Q-Orbitrap-MS; immunoassay (research grade) |
Bioactives Matrix
Class I: Core Ganoderic and Ganoderenic Acids
Candidate compounds for a Ganoderma lucidum quality scope.
| Compound · CAS / formula | Source matrix | Mechanism / evidence | Specificity | Std. status | Analytical note |
|---|---|---|---|---|---|
| Ganoderic acid A CAS 81907-62-2 · C30H44O7 · 516.67 | FB (primary), spore | NF-κB, IL-6 / IL-1β; antitumor; hepatoprotective | G. lucidum primary marker | Certified Primary | HPLC-DAD 252–257 nm; USP listed |
| Ganoderic acid B CAS 81907-61-1 · C30H44O7 · 516.67 | FB, spore | Hepatoprotective; anti-histamine; anti-HIV protease | Co-monitored with GA-A | Available | Co-elutes with GA-A in low-res; UPLC required |
| Ganoderic acid C1, C2, C6 C1, C2: C30H44O7 · C6: TBD | FB; C6 also mycelium | Antitumor; G1 arrest; cytotoxic cell models | G. lucidum; ChP-listed (C2) | C2 Avail.; C1, C6 Limited | C2 in ON-052 9.24 min; C1 coelutes with GA-D, MS/MS needed |
| Ganoderic acid D C30H44O8 · 532.7 | FB | Cytotoxic (MCF-7, HepG2, HeLa, Caco-2, HCT-116) | G. lucidum | Certified Primary | HPLC-DAD 252 nm; in ON-052; coelutes with C1 (see note) |
| Ganoderic acid F CAS 98665-15-7 · C32H42O9 · 570.7 | FB | Antitumor (GLE studies) | G. lucidum | Available | UV 252 nm; ON-052 26.4 min |
| Ganoderic acid G, H, J G: C30H44O8 · H: C32H44O9 · J: TBD | FB; H also in mycelium | G: PCA quality discriminator. H: best-characterized PK. J: anti-inflammatory triterpene | G. lucidum | G, J Limited / H Available | PCA fingerprint (G); LOD-LLOQ for H; J UV-active 252 nm |
| Ganoderic acid T, DM T: CAS 103992-91-2 · C36H52O8 / DM TBD | Mycelium (T) / FB (DM) | T: mito. apoptosis, MMP-9. DM: pathway anchor, anti-inflammatory | G. lucidum | Limited / Validation | Method 2 (MS/MS); mycelial marker |
| Ganoderenic acids A–H Unsaturated GA analogues. CAS / formula TBD. | FB (alongside GAs) | Co-occur with GAs; same biosynthetic family; UV-active | G. lucidum; some in G. applanatum | GE-B/C/D Avail.; A,E,F,G,H Limited | HPLC-DAD 252–257 nm; in STAG-A |
STAG-A · Total Ganoderic Acids (Fruiting Body)
Published Compound List
STAG-A is the explicit compound list behind any "Total Ganoderic Acids" claim for fruiting-body products:
GA-A, B, C1, C2, C6, D, F, G, H, J, plus ganoderenic acids A, B, C, D, E, F, G, H. Ganoderenic acids co-occur with GAs and are unsaturated derivatives of them, analogous to how the USP ashwagandha monograph counts selected withanosides in Total Withanolides.
Analytical caveat: ganoderic acid C1 and ganoderic acid D can coelute chromatographically; a triple quadrupole MS/MS transition set is needed to distinguish them with confidence during method development and validation. Omnient's current method measures GE-B, C, D, E; GE-A is included once validated; GE-F, G, H stay in unless validation shows otherwise. GA-T and GA-DM enter through the alcohol method and the mycelium method.
Ganoderic Acids
GA-A, B, C1, C2, C6, D, F, G, H, J
Ganoderenic Acids
GE-A, B, C, D, E, F, G, H
Class II: Lucidenic Acids (C27)
Lucidenic acids are the second major triterpenoid group in G. lucidum and the chemical class most often missing from existing panels. They are routinely present in commercial fruiting body products at mg / g levels. Their pharmacology (ACE2 inhibition, AChE and BChE inhibition, PTP1B inhibition, anti-viral activity) is not duplicated by ganoderic acids, which makes their omission a scope problem, not a completeness one.2
| Lucidenic acid | Formula · MW | Bioactivity | Typical level (FB) | Std. status | Method |
|---|---|---|---|---|---|
| LA-A | C27H38O6 · 458.59 | PC-3 IC50 35 µM; ACE2 IC50 2 µmol/mL; AChE IC50 24 µM | ≤ 2.8 mg/g | Commercially Available | HPLC 252 nm; ON-052 ~20.4 min |
| LA-B | C27H38O7 · 474.59 | HL-60 IC50 45 µM; MMP-9; antioxidant | mg/g range | Commercially Available | STAG-LA candidate |
| LA-C | C27H40O7 · 476.61 | A549 52 to 85 µM; EBV / HBV anti-viral | mg/g range | Limited | UPLC resolves from LA-B |
| LA-D1, D2 | C27H34O7 / C29H38O8 | Anti-cancer; anti-inflammatory; D2 EBV anti-viral, ID50 0.11 mg/ear | D2: 1.5 to 2.2 mg/g | D2 Limited / D1 Validation | Spore-method co-target (D2) |
| LA-E1, E2 | C27H38O7 / C29H40O8 | E2 HMG-CoA IC50 42.9 µM; anti-inflammatory | E2: 2.2 to 3.3 mg/g | E2 Limited / E1 Validation | Method 1 / spore co-target |
| LA-F, LA-G | C27H36O6 / C27H40O7 | F: anti-viral (EBV). G: antioxidant component | Trace to mg/g | Validation Target | Method 1 / MS/MS |
| LA-H | C27H40O7 · 476.61 | PTP1B IC50 7.6 to 41.9 µM (antidiabetic) | mg/g range | Limited | Method 1 |
| LA-I, J, K, L, M | C27 series · trace | I, M immunomodulatory; J anti-cancer; K antioxidant; L anti-inflammatory | Trace | Validation Target | MS/MS |
| LA-N | C27H40O6 · 460.61 | HL-60 IC50 64.5 µM; AChE IC50 26 µM; ↓TG 30% | 257 to 884 µg/g | Commercially Available | Method 1; spore co-target |
| LA-O | C27H40O7 · 476.61 | HIV RT IC50 67 µM; DNA polymerase α/β inhibitor | mg/g range | Limited | Method 1 |
| LA-P | C29H42O8 · 518.64 | Anti-inflammatory ID50 0.29 mg/ear; EBV anti-viral | Trace to mg/g | Validation Target | MS/MS |
| LA-Q | C27H40O6 · 460.61 | α-Glucosidase IC50 60.1 µM; aldose reductase inhibitor | mg/g range | Limited | Method 1 |
| LA-R | C29H40O9 · 532.62 | Anti-inflammatory (RAW264.7 NO −20%) | Trace | Validation Target | MS/MS |
STAG-LA · Total Lucidenic Acids (Optional Fruiting-Body Claim)
Recommended secondary group for the fruiting body method: LA-A, B, C, D2, E2, N, Q, plus the anti-viral and HIV-RT pair LA-O and P. LA-N and LA-A are commercially available reference standards today; the rest are validation targets best run with relative response factors (RRFs) calibrated from LA-A as the anchor.
Spore-Enriched GAs, Ganolucidic Acids, Triterpenoid Alcohols
Spore preparations have a chemical fingerprint distinct from the fruiting body. Greek-letter ganoderic acids (α to θ) are spore-enriched. Ganosporelactones are spore-specific. Ganolucidic acids index minor gill-surface constituents. Triterpenoid alcohols are UV-quiet and live on the UPLC-MS/MS panel rather than HPLC-DAD. Ganoderenic acids are discussed with the core acidic-triterpene set in Class I, since they belong in the Total Ganoderic Acids STAG.1,9
| Compound | Source matrix | Mechanism / role | Specificity | Std. status | Analytical note |
|---|---|---|---|---|---|
| Ganoderic acid α (alpha) | Spore (primary) | 12β-acetoxy variant; major spore compound | Spore-marker | Limited | MS/MS confirmation; UV-quiet vs Type I |
| Ganoderic acid β (beta) | Spore | Anti-HIV-1 protease (IC50 ~20 to 90 µM) | Spore-marker | Limited | MRM TBD by vendor certificate |
| Ganoderic acid γ, δ, ε, ζ, η, θ | Spore | Trihydroxy / tetrahydroxy; C-23 isomers | Spore-fingerprint | Validation Target | MS/MS preferred; profiles distinguish lots |
| Ganosporelactone A, B | Spore (specific) | Lactone variants identified by UHPLC-Q-Orbitrap-MS | Spore authenticity | Custom Synthesis Req. | High-resolution MS only; reference TBD |
| Ganolucidic acid A, B, D, E | Fruiting body (gill surface) | Minor triterpenoids; structural markers | G. lucidum minor constituents | Custom Synthesis Req. | Trace-level; confirm during validation |
| Ganodermanondiol | Fruiting body, mycelium | Immunomodulatory; strong anti-tumor | Ganoderma alcohol class | Limited | Method 2 target (UPLC-MS/MS) |
| Ganodermanontriol; Ganoderiol A, C to J | Fruiting body | Immunomodulatory; antitumor (Ganoderiol F IC50) | Ganoderma alcohol class | Limited | Method 2; multiple isomers |
| Lucidumol A, B; Lucialdehyde A to E | Spore; fruiting body | Structural markers; lucialdehyde C cytotoxic vs T-47D | Spore / G. lucidum | Validation Target / Limited | Often co-extracted with GA-α |
| Applanoxidic acid G, H | G. applanatum | 7α,8α-epoxy moiety; cytotoxic | Cross-species marker | Custom Synthesis Req. | Relevant if scope extends across Ganoderma |
Polysaccharides, Sterols, Nucleosides, Meroterpenoids, FIPs
| Compound / class | Source matrix | Mechanism / role | Specificity | Std. status | Method |
|---|---|---|---|---|---|
| β-(1,3)-D-glucan (high-MW, branched) | FB, mycelium | TLR2 / Dectin-1; primary immunostimulant | Fungal; Ganoderma-relevant | Commodity (Megazyme) | Enzymatic; HPLC monosacch. |
| β-(1,6)-D-glucan side chains | FB, mycelium | Enhances Dectin-1 receptor binding | Fungal | Available | GC-MS after hydrolysis |
| α-D-glucan (starch) | Grain substrate residue | Negative quality indicator (myceliated grain) | Substrate, NOT Ganoderma | Commodity | Enzymatic starch; NMR α/β |
| Ergosterol | FB, mycelium | Anti-inflammatory; provitamin D2; membrane marker | Fungal authenticity anchor | Certified Primary | HPLC-UV 280 nm |
| Ergosterol peroxide | FB | HepG2 antitumor (Foxo3 / Bax / Puma); anti-obesity | Ganoderma; some fungi | Available | HPLC-UV 280 nm |
| Adenosine | FB, mycelium, spore | Anti-platelet; lipid-lowering; vasodilatory | Ganoderma nucleoside | Certified Primary | HPLC-UV 254 / 260 nm |
| Uridine, inosine, guanosine, thymidine, cytidine | FB, mycelium, spore | Anti-inflammatory, neuroprotective, immunomod. | Generic nucleosides | Available | HPLC-UV 254 nm; <20 min |
| Lingzhiol; Lingzhines A–E; Chizhines A–F; Ganomycin A,B,J | G. lucidum meroterpenoids | Renoprotection (Smad3, Nrf2); HMG-CoA (Ganomycin J); aldose reductase | G. lucidum chemotype | Limited / Validation | UPLC-Q-Orbitrap-MS; HRMS |
| Spiroapplanatumines A–Q; Cochlearols A–K | G. applanatum; G. cochlear | JAK3 IC50 7–35 µM (spiro); cochlearols: renoprotective, antioxidant | Cross-species markers | Custom Synth. | HRMS |
| Ling Zhi-8 (LZ-8); FIP-glu | FB, mycelium | Lectin-like; immunoglobulin stimulation | Ganoderma immunoprotein | Limited (recomb.) | Immunoassay (research) |
Meroterpenoids are a surveillance target appropriate for research-grade profiling (UPLC-Q-Orbitrap, HRMS) and are not yet suitable for routine certificate-of-analysis claims; reference standards, RRFs, and inter-lab validation data are not in place for most members of this class. FIPs (fungal immunomodulatory proteins, e.g. Ling Zhi-8) are a protein / peptide class with distinct extraction requirements and bioavailability considerations, so a standard small-molecule extract panel does not also measure FIP content.
Practical Implication
Polysaccharide quality must be linkage-resolved. STAG-PS = enzymatic β-(1,3/1,6)-D-glucan PLUS a co-reported α-D-glucan (starch) value as a substrate indicator. A single colorimetric "total polysaccharides" result should not be accepted as a grouped claim. There is too much opportunity for adulteration with that methodology. Additionally, the current methodology for testing beta-glucans is the Megazyme enzymatic kits. These have issues with adulteration and poor replication lab-to-lab as well. It should eventually be phased out for more accurate methods, like HP-SEC.
STAG Proposal
If a Label Says "Total," Show the List
A STAG, or standardized target analyte grouping, is the explicit, controlled list of compounds that a grouped assay claim actually counts. It's a clearly defined list of compounds being grouped together for a specific claim. If a Reishi extract is labeled "total ganoderic acids 4%," the STAG declares which ganoderic acids the lab summed to get to 4%. STAG-A might be sixteen acids and ganoderenic acids. STAG-USP might be ten. Both are honest. They are not comparable to each other until the relevant STAGs are compared to each other. This is pertinent to plants as well. When claiming a total withanolide result for Ashwagandha, the STAG should be listed out; otherwise you could be comparing two totally different groups of compounds, both being labeled as "Total Withanolides." The STAG allows both scientists and consumers to understand what is being tested and standardized to.
For Consumers
When a product says "total ganoderic acids" on the label, ask which acids are counted. A STAG listed on a certificate of analysis is the solution to the issue. Without a STAG, consumers might be comparing two products to each other using very different sets of standards.
For Brands and Manufacturers
Pick a STAG you will use to standardize your product, then publish it. Two suppliers running the same STAG can be compared directly. Two running different STAGs cannot, regardless of whose number is bigger. Understand your STAG and what it is measuring, so you can intelligently set specifications for your products.
For Analytical Labs
A STAG is an explicit grouping of analytes, not a new instrument. It can be the same column, same gradient, and same detector. The difference is in the integration: integrated peaks are listed by name, and the STAG ID is carried alongside the total. It's audit-friendly, reviewer-friendly, and provides meaningful information to brands and consumers.
STAG-A · Total Ganoderic Acids — Fruiting body · published list
Figure · STAG-A as a Container: Two Subgroups, One Declared Total
Ganoderic Acids
GA-A, B, C1, C2, C6, D, F, G, H, J
Ganoderenic Acids
GE-A, B, C, D, E, F, G, H
Reishi Is Three Products. Quality Should Be Read That Way.
Reishi commerce flows through three categorically different material types. The chemistry is not the same in any two of them. A standard that pretends otherwise pushes brands and labs into impossible comparisons.
Fruiting Body
Acidic triterpenes, ergosterol, β-glucan
Mycelium
β:α glucan ratio, sterols, nucleosides
Spores
Spore-based GAs, lucidumols, sporoderm
| Material type | Defining chemistry | What the test must catch | STAG bundle |
|---|---|---|---|
| Fruiting body (extract, powder, concentrate) | Acidic triterpenes (GA and ganoderenic acids; lucidenic acids); ergosterol; β-glucan | Mycelium-on-grain substituted as fruiting body; loss of triterpene during processing | STAG-A + STAG-LA (HPLC-UV) STAG-ALC (UPLC-MS/MS) |
| Mycelium / full-spectrum (liquid or solid-state ferment) | β/α-glucan ratio; ergosterol and ergosterol peroxide; nucleosides; selected mycelial triterpenoids (GA-T, GA-H) | Grain-substrate dilution; missing β-glucan signature; absence of fruiting-body triterpenes | STAG-PS (with α-glucan) STAG-MYC (see below) |
| Spore (broken vs unbroken sporoderm) | Spore-enriched GAs (α, β, γ, ε); ganosporelactones A and B; spore lucidenic sub-set; lanostane alcohols | Unbroken sporoderm (low bioavailability); fruiting-body chromatograms mis-attributed to spore | STAG-SPR + STAG-ALC subset plus sporoderm status |
STAG-MYC
Mycelium Identity Panel
For mycelium and full-spectrum products (liquid-fermented or solid-state). Quantitative, reported on the COA:
· Ergosterol (HPLC-UV 280 nm; anchor)
· Ergosterol peroxide (HPLC-UV 280 nm)
· Adenosine (HPLC-UV 254 nm; anchor)
· Uridine, inosine, guanosine (nucleoside fingerprint)
· GA-A, GA-H, GA-T (UPLC-MS/MS, mycelial triterpenoids)
Co-reported with STAG-PS (β-glucan and α-glucan separately) and a fermentation-process notes section where applicable. Reference standards: ergosterol (ChromaDex), adenosine (Cayman), GA-A (Cayman); the rest by validated relative response factors.
· Ergosterol (HPLC-UV 280 nm; anchor)
· Ergosterol peroxide (HPLC-UV 280 nm)
· Adenosine (HPLC-UV 254 nm; anchor)
· Uridine, inosine, guanosine (nucleoside fingerprint)
· GA-A, GA-H, GA-T (UPLC-MS/MS, mycelial triterpenoids)
Co-reported with STAG-PS (β-glucan and α-glucan separately) and a fermentation-process notes section where applicable. Reference standards: ergosterol (ChromaDex), adenosine (Cayman), GA-A (Cayman); the rest by validated relative response factors.
STAG-SPR
Spore-Product Panel
For spore, spore oil, and spore extract products. Quantitative, reported on the COA:
· Ganoderic acid α, β, γ, ε (UPLC-MS/MS; spore-enriched)
· Lucidenic acid D2, E2, N, A (HPLC-UV + UPLC-MS/MS)
· Lucidumol A, B (UPLC-MS/MS; spore alcohol markers)
· Ergosterol, ergosterol peroxide (HPLC-UV 280 nm)
Exploratory / report-when-present (Validation Target tier): ganosporelactone A, B (UHPLC-Q-Orbitrap-MS), GA-δ, ζ, η, θ. Co-reported with sporoderm status (microscopy, particle-size, dissolution check) for bioavailability context.
· Ganoderic acid α, β, γ, ε (UPLC-MS/MS; spore-enriched)
· Lucidenic acid D2, E2, N, A (HPLC-UV + UPLC-MS/MS)
· Lucidumol A, B (UPLC-MS/MS; spore alcohol markers)
· Ergosterol, ergosterol peroxide (HPLC-UV 280 nm)
Exploratory / report-when-present (Validation Target tier): ganosporelactone A, B (UHPLC-Q-Orbitrap-MS), GA-δ, ζ, η, θ. Co-reported with sporoderm status (microscopy, particle-size, dissolution check) for bioavailability context.
How This Maps to Real Product Formats
The three STAG bundles described on the previous page are not abstractions. They correspond to material formats already on the market today. Three commercial Reishi products illustrate how a bioactives-first standard maps onto real certificate-of-analysis work.
Fruiting-Body Extract · STAG-A / STAG-LA Territory
Red Reishi Mushroom Capsules, 9% Ganoderic Acids
A G. lucidum fruiting-body extract standardized to 9% ganoderic acids verified by UPLC, in 150 mg capsules delivering 13.5 mg ganoderic acids per serving. A pure fruiting-body extract of this kind is exactly what the STAG-A panel (Total Ganoderic Acids) and the STAG-LA panel (Total Lucidenic Acids) were drafted to cover.
Multi-Extract Blend · Declare Every STAG in Scope
LucidiMax Capsules
Combines a G. lucidum fruiting-body extract, broken-spore powder, a dual extract, and a proprietary Reishi extract in a single capsule. The label discloses 200 mg β-glucans, cracked spores, 16 mg ganoderic acids, 6 mg unique triterpenes, and sodium caprate. A blend like this is exactly the case where each fraction needs its own declared STAG: STAG-A (fruiting-body ganoderic acids), STAG-PS (β-glucan with α-glucan reported separately), and the spore-relevant analyte set, all on the same certificate of analysis.
Spore Oil · STAG-SPR + Sporoderm Status
LucidiSPORE Supercritical CO2 Reishi Spore Oil
A Red Reishi spore oil produced from cracked spores by solventless supercritical CO₂ extraction, consistently testing at 30% triterpenoids. A product like this belongs in the spore-method discussion, where spore-enriched Greek-letter ganoderic acids, lucidumols, the spore lucidenic sub-set, and sporoderm status matter more than fruiting-body-only assumptions about which compounds are present.
Method Practicality
Validate Once with Standards. Run Routine QC with Relative Response Factors.
A common objection to a broad STAG: not every compound has a primary reference standard available on a vendor shelf. True for method development and validation, where you do need the standards you can acquire. Largely irrelevant for routine QC, where botanical and pharmaceutical labs have used relative response factors (RRFs) for decades. Calibrate against one or a small number of commercially available anchor standards once, lock the RRFs during validation, and run routine QC against the anchors plus the validated factors.23
Practical Implication
The standard should specify (1) which compounds in each STAG are anchor (primary-standard) targets and (2) which compounds may be quantified by validated RRF. Suggested anchors: GA-A for the ganoderic STAG, LA-A for the lucidenic STAG, ergosterol for the sterol STAG, adenosine for the nucleoside STAG, and a Megazyme-traceable preparation for the linkage-specific β-glucan STAG. Standard availability is a validation cost, not a scope constraint. For now, the Megazyme KYBGL kits are the best way to measure alpha and beta glucans, even though there are methodological limitations. Enhanced methodologies should be developed to fully characterize the polysaccharide profiles of Reishi in the future. Not all alpha-glucans are bad, and not all beta-glucans are good. It is the size of the polysaccharide chains and their branching structures that matter. Properly measuring those is the next frontier in fungal quality science that Omnient Labs is currently working on.
| Category | Typical example | Use in routine QC |
|---|---|---|
| Commercially Available · Certified Primary Std. | GA-A (Cayman), LA-A, Ergosterol (ChromaDex), Adenosine | Anchor for routine QC; primary calibration |
| Commercially Available | GA-B, GA-C2, GA-D, GA-F, GA-H; LA-N | Validation calibration; can be RRF-quantified in QC |
| Commodity / Widely Available | Megazyme β-glucan kit; α-glucan kit; common sterols | Use as supplied; lot-traceable |
| Limited | GA-G, GA-T, LA-B / C / D2 / E2 / H / O / Q | RRF-quantified after validation |
| Custom Synthesis Req. | Ganosporelactone A / B; some meroterpenoids; trinor analogues | Validation Target only; deferred from initial scope |
| Validation Target | Trace lucidenic acids (F, G, J, K, L, M, P, R) | MS/MS confirmation; report when present |
Fruiting Body Methods · HPLC-UV
Method 1 — Acidic Triterpenes: Ganoderic, Ganoderenic, Lucidenic
Method 1 is the chromophore-rich workhorse. The acidic, conjugated lanostane triterpenes (ganoderic and ganoderenic acids of the Δ8,9 / Δ8,20E series, plus the lucidenic acids) absorb strongly in the 252 to 257 nm region and resolve cleanly on a C18 column with an acetonitrile / aqueous phosphoric- or formic-acid gradient. The method is fully validated in the published literature for linearity, precision, accuracy, and recovery.7
| STAG candidate | RT (min, ON-052) | Bioactivity / role | Std. status |
|---|---|---|---|
| Ganoderenic acid C | 8.45 | Type II GA; cultivation discriminator | Commercially Available |
| Ganoderic acid C2 | 9.24 | Antitumor; ChP-listed | Commercially Available |
| Ganoderic acid C6 | 9.91 | Cytotoxic in cell models | Limited |
| Ganoderic acid G | 10.78 | Chemometric quality discriminator | Limited |
| Ganoderenic acid B | 11.78 | Type II GA; antitumor | Limited |
| Ganoderic acid B | 12.76 | Hepatoprotective; anti-HIV protease | Commercially Available |
| Ganoderenic acid E | 15.26 | Type II GA | Limited |
| Ganoderic acid A (anchor) | 17.30 | USP marker; primary calibration anchor | Commercially Available · Certified Primary Std. |
| Ganoderic acid H | 19.63 | Best-characterized PK; UPLC-MS validated | Commercially Available |
| Lucidenic acid A | 20.41 | ACE2 IC50 2 µmol/mL; AChE; anti-cancer | Commercially Available |
| Ganoderenic acid D | 21.54 | Cultivation discriminator | Commercially Available |
| Ganoderic acid D | 23.21 | Cytotoxic; HPLC-DAD validated | Commercially Available · Certified Primary Std. |
| Ganoderic acid F | 26.42 | Antitumor; UV 252 nm | Commercially Available |
Method 1 · Conditions (Recommended Starting Point)
Column: C18, 1.7 µm, 100 × 2.1 mm. Mobile phase A: 0.05% H₃PO₄ in water. Mobile phase B: acetonitrile. Gradient: 30% B to 70% B over 28 min. Detection: PDA 252 nm primary, 257 nm secondary (Omnient Labs uses PDA Ch1 257 nm at 4.8 nm bandwidth). Injection: 1 µL. Extract: 95 to 100% ethanol. Run time ≤ 30 min on UPLC. Coelution caveat: ganoderic acid C1 and ganoderic acid D can coelute on this gradient; a triple quadrupole MS/MS transition set is needed to distinguish them during method development and validation.
Ganoderic acid A · Method 1 anchor
C₃₀H₄₄O₇ · 516.67 g/mol · UV-active 252–257 nm
PubChem CID 471002
Fruiting Body Methods · UPLC-MS/MS
Method 2 — Triterpenoid Alcohols and 5α-Reductase Inhibitors
Lanostane alcohols (ganodermanondiol, ganodermanontriol, ganoderiols A and C to J, ganoderal A / B, lucidumols A / B, epoxyganoderiols, ganoderitriol M) and selected Type II Δ7,9(11) variants act as 5α-reductase inhibitors and contribute meaningfully to the Ganoderma activity profile. They have either poor or no chromophores, which is why they do not show up effectively on HPLC-DAD chromatograms. UPLC-MS/MS in MRM mode is the appropriate platform.8,22
These analytes are absent or present only at trace levels in myceliated grain substrates. Their inclusion creates a fruiting body and spore authenticity panel that runs in parallel to Method 1: when Method 1 reports a strong total ganoderic acid value, Method 2 confirms (or fails to confirm) the lanostane alcohol fingerprint expected of an authentic fruiting body or spore preparation. Methods 1 and 2 used together are difficult to fool with a substrate-dilution product.
| STAG candidate (Method 2) | Class | Standard status |
|---|---|---|
| Ganodermanondiol | Lanostane alcohol | Limited |
| Ganodermanontriol | Lanostane triol | Limited |
| Ganoderiol A | Lanostane diol | Validation Target |
| Ganoderiol C to J | Lanostane alcohols | Validation Target |
| Ganoderal A, B | Lanostane aldehyde-alcohol | Limited |
| Lucidumol A, B | Spore-enriched alcohol | Validation Target |
| Epoxyganoderiol B, C | Epoxy alcohol | Validation Target |
| Ganoderitriol M | Lanostane triol | Validation Target |
| Ganoderic acid α (alcohol-region cluster) | Spore Type II GA | Limited |
| Lucialdehyde C (anchor option) | Triterpenoid aldehyde | Limited |
STAG Note
STAG-ALC, Lanostane Alcohols (UPLC-MS/MS) is by design a research-grade STAG with a published compound list and a clearly labeled Validation Target tier. The STAG's value is the presence or absence of these compounds, not as a high-precision absolute quantitation method. In the future, once reference standards become available, more accurate quantitation methods can be created and validated.
Lucidumol A · Method 2 lanostane alcohol
C₃₀H₄₆O₄ · spore-enriched alcohol · UV-quiet, MRM-detected
PubChem CID 475410
Mycelium Methods
Mycelium/Full Spectrum Methods — Linkage-Specific Glucan, Sterols, Nucleosides, Process Markers
Mycelial preparations (liquid-fermented biomass, solid-state-fermented biomass, and "full-spectrum" preparations that include the substrate) are chemically distinct from fruiting body extracts. Acidic triterpenes are sparse; ergosterol and nucleosides remain informative; glucan profile is the dominant analytical technique. The mycelium method must distinguish authentic mycelial chemistry from substrate dilution.3,6
| Analyte / panel | Method | Role in mycelium QC |
|---|---|---|
| β-(1,3)-D-glucan + β-(1,6) side chains | Megazyme enzymatic specific assay; GC-MS after hydrolysis | Primary mycelial bioactive identity |
| α-D-glucan (starch) | Enzymatic starch assay; NMR α/β resolution | Negative indicator: residual grain substrate |
| Glucan ratio β:α | Calculated from above two assays | Quantifies substrate dilution |
| Ergosterol | HPLC-UV 280 to 281 nm | Fungal-biomass authenticity |
| Ergosterol peroxide | HPLC-UV 280 nm | Sterol bioactive marker |
| Adenosine, uridine, inosine, guanosine | HPLC-UV 254 nm | Nucleoside fingerprint; tissue-discriminator |
| Selected mycelial triterpenoids (GA-A, GA-H, GA-T) | UPLC-MS/MS | Confirm Ganoderma mycelial chemistry vs. neutral biomass |
| Fermentation-process markers (where defensible) | UPLC-MS/MS; HRMS | Process traceability; lot consistency |
Practical Implication
The mycelium method's most important number is the β to α glucan ratio, not the total polysaccharide value. A high total polysaccharide reading on a mycelium-on-grain (or full-spectrum) product reflects starch, not Reishi. The mycelium standard for quality should require linkage-specific reporting, with α-D-glucan declared as a process indicator on the certificate of analysis. This is where HP-SEC is going to be needed. Also, there are mycelium-specific ganoderic acids and triterpenoids that may be present that could be assayed using either HPLC/UPLC-UV or LC-MS-MS. Fruiting body ganoderic acids could also theoretically be present, if the grower lets their process reach the fruiting stage and optimizes for these compounds. However, in extensive market research testing performed at Omnient Labs, we have yet to find a single batch of mycelium-on-grain or full-spectrum Reishi, from any manufacturer in the world, that contains measurable amounts of ganoderic acids or triterpenoids. They have all been completely devoid of these bioactive compounds. That is not to say it is not possible to make these bioactives in that process, but that will be up to the full spectrum growers to figure out in their process optimization. Additionally, ergosterol is a good marker compound to test for the presence of Reishi fruiting body in a sample. If a mycelium-on-grain/full-spectrum product contains little to no ergosterol, there is likely very little fruiting body material in the sample.
Ergosterol · Mycelium method anchor
C₂₈H₄₄O · 396.65 g/mol · fungal sterol; HPLC-UV 280 nm
PubChem CID 444679
Spore Methods
Greek-Letter GAs, Ganosporelactones, Lucidenic D2 / E2 / N / A, Sporoderm
Spore products (broken-sporoderm or unbroken) carry a chemically distinct fingerprint dominated by Greek-letter ganoderic acids (α, β, γ, δ, ε, ζ, η, θ), ganosporelactones A and B, lucidumols A and B, and a particular lucidenic acid sub-set (D2, E2, N, A). The spore method has to address two things at once: chemistry, and bioavailability. Unbroken sporoderm is functionally non-bioavailable, so the certificate of analysis should report sporoderm status alongside chemical fingerprint.9,10
| Analyte / panel | Method | Role |
|---|---|---|
| Ganoderic acid α (anchor) | UPLC-MS/MS | Major spore Type II GA |
| Ganoderic acid β, γ, δ, ε, ζ, η, θ | UPLC-MS/MS | Spore-fingerprint cluster |
| Ganosporelactone A, B | UHPLC-Q-Orbitrap-MS | Spore-specific lactones; authenticity |
| Lucidenic acid D2 (1.5 to 2.2 mg/g) | HPLC-UV 252 nm + UPLC-MS/MS | Spore co-target; anti-inflammatory marker |
| Lucidenic acid E2 (2.2 to 3.3 mg/g) | HPLC-UV + UPLC-MS/MS | Spore co-target; HMG-CoA inhibitor |
| Lucidenic acid N (257 to 884 µg/g) | HPLC-UV + UPLC-MS/MS | AChE / TG-lowering marker |
| Lucidenic acid A | HPLC-UV | ACE2 / AChE marker |
| Lucidumol A, B | UPLC-MS/MS | Spore-enriched alcohol markers |
| Ergosterol, ergosterol peroxide | HPLC-UV 280 nm | Sterol authenticity |
| Sporoderm status (broken / unbroken) | Microscopy + particle-size + dissolution check | Bioavailability context (report alongside) |
STAG-SPR Recap
STAG-SPR = GA-α, β, γ, ε (UPLC-MS/MS); ganosporelactones A and B where reference material allows (UHPLC-Q-Orbitrap-MS, Validation Target); plus the spore lucidenic sub-set LA-D2, LA-E2, LA-N, LA-A; plus lucidumol A and B; plus ergosterol and ergosterol peroxide. A spore certificate of analysis should declare STAG-SPR values alongside sporoderm status and a particle-size summary. The two together are the bioavailability signal a buyer needs.
Lucidenic acid D2 · Spore-method co-target
C₂₉H₃₈O₈ · spore lucidenic; D2 EBV anti-viral, ID50 0.11 mg/ear
PubChem CID 23247891
Example Lab Data
What Bioactive-Centered Testing Reveals on a Real Sample
The dataset below was generated by Omnient Labs on a Reishi mushroom extract, sample ON-052 #RBLZ260327. The point is not the headline number, the point is that the same chromatogram can be reported under two different STAGs. The Omnient expanded method quantifies 13 ganoderic / ganoderenic / lucidenic compounds; the USP <2102> reishi monograph quantifies a narrower set of 10. Both totals are valid; they are not the same number because they integrate different compound lists.
23.394% Omnient Expanded · Mean 13 analytes · P1 23.451%, P2 23.337%
21.442% USP <2102> · Mean 10 analytes · P1 21.496%, P2 21.389%
+9.1% Method-Scope Gap Same sample, different declared list
13 Analytes Quantified Omnient expanded STAG-A scope
| # | Compound | RT (min) | Area | Omnient (%) | USP (%) |
|---|---|---|---|---|---|
| 3 | Ganoderenic acid C | 8.452 | 896,412 | 0.463 | 0.463 |
| 4 | Ganoderic acid C2 | 9.239 | 1,492,452 | 2.101 | 2.101 |
| 5 | Ganoderic acid C6 | 9.906 | 381,458 | 0.695 | 0.695 |
| 6 | Ganoderic acid G | 10.778 | 1,357,405 | 2.034 | 2.034 |
| 7 | Ganoderenic acid B | 11.776 | 989,050 | 0.588 | 0.588 |
| 8 | Ganoderic acid B | 12.755 | 1,642,057 | 2.057 | 2.057 |
| 9 | Ganoderenic acid E | 15.261 | 2,323,585 | 1.260 | not counted |
| 10 | Ganoderic acid A (anchor) | 17.299 | 4,000,945 | 5.167 | 5.167 |
| 11 | Ganoderic acid H | 19.629 | 1,437,254 | 2.914 | 2.914 |
| 12 | Lucidenic acid A (peak ID only) | 20.410 | n/a | 0.000 | not counted |
| 13 | Ganoderenic acid D | 21.541 | 1,277,963 | 0.743 | not counted |
| 14 | Ganoderic acid D | 23.213 | 2,310,769 | 2.895 | 2.895 |
| 15 | Ganoderic acid F | 26.420 | 1,609,018 | 2.535 | 2.535 |
| Σ Total · Omnient expanded (13 analytes), P1 | 23.451% | ||||
| Σ Total · USP <2102> (10 analytes), P1 | 21.496% | ||||
Method PDA Ch 1 at 257 nm at 4.8 nm · Waters UPLC + Empower 3 · GA-A reference (Cayman Lot 0649826-18) · Acquired 4/14/2026; processed 4/15/2026. USP (%) column shows values only for the 10 compounds the USP <2102> reishi monograph quantifies; the three Omnient-only analytes are marked not counted. Lucidenic acid A is in the Omnient list but contributed 0% in this run because the analyte is not present in this extract under method conditions, not because of a calibration issue.
Method Advancement
What the Current Chromatogram Already Shows
The current Omnient fruiting-body chromatogram shows many more peaks than USP <2102> quantifies. Each unidentified peak is a validation candidate: once identity is confirmed by MS and the RRF is locked against a reference standard, the peak can join the STAG.24
15 Validated Compounds RT-locked, RRF in progress
13 Chromatographic Peaks 2 coelution pairs collapse 15 → 13
13 Candidate Unknowns high / med / low confidence
2 Coelution Pairs GA-J / GA-F; GA-C1 in D-region
| Validated additions beyond USP | RT | Next validation priorities | RT |
|---|---|---|---|
| Lucidenic acid A | 19.66 | Ganoderic acid AM1 (high) | 9.85 |
| Ganoderic acid C1 (in D region) | 21.60 | Lucidenic acid N (high) | 10.43 |
| Ganoderic acid J (with GA-F) | 26.43 | Ganoderenic acid G (high, major) | 14.18 |
| Ganoderenic acid E | 15.19 | Ganoderic acid TR (med.) | 16.09 |
| Ganoderic acid C6 · USP set retained (10 compounds) | 24.96 | Ganoderic acid DM (high) | 24.80 |
| Ganoderic acid Me / Mf (med., major) · plus MW-568 late zone | 25.65+ |
Why 15 Compounds Can Be 13 Peaks
Our fruiting-body method tracks 15 validated compounds across 13 chromatographic peaks. The count differs because GA-J coelutes with GA-F, and GA-C1 coelutes in the D-region peak under the current chromatographic conditions. On single quadrupole instruments the mass signals are not distinct enough to assign those coeluting analytes with the confidence needed for final method expansion. Omnient Labs is therefore moving this work onto a Xevo TQ-S Micro triple quadrupole so the transition set, peak identity, and relative response factors can be validated before those peaks are added to routine reporting.
For single-quadrupole labs adopting Method 1 today: report the two coelution pairs as combined peaks, GA-C1+D and GA-J+F, on the certificate of analysis until MS/MS confirmation is available. The STAG total remains valid when each coelution pair is declared on the COA.
Forward-Looking Note
Why a Broader STAG Can Move the Apparent Total Upward
Two observations on the ON-052 dataset are worth raising as forward-looking analytical hypotheses, not as already-validated results. The first concerns Lucidenic acid A. The peak label appears in the report at retention time 20.41 minutes, but the area and concentration are zero. This is not a calibration issue. It means this specific extract, run under these method conditions, does not contain a quantifiable amount of LA-A. The peak label was reserved by the method; the analyte is simply not present here. Other peaks in the chromatogram, however, are present but are not yet integrated or quantified by the active method. Some of those unknown or currently unvalidated peaks may turn out to be additional bioactives. As they are identified and validated, the STAG can expand to include them, and the reported total percentage may rise. Not because the product changed, but because the method now counts more of the real chemistry.
The second observation concerns the gap between the Omnient expanded total (23.394%) and the USP <2102> total (21.442%) on the same extract: roughly 1.95 absolute percentage points are accounted for by ganoderenic acids E and D and by Lucidenic acid A (present in the Omnient list, contributing 0% in this run) that the Omnient method integrates and the USP monograph does not. Expanding the integrated panel further (additional ganoderenic acids beyond those currently quantified, GA-T in mycelial-blended materials, Type II spore congeners where present) is reasonably expected to push the reported total higher after validation, even though the underlying material has not changed.
Forward-Looking Note
This is an analytical observation, not a claim of higher product potency. The chemical composition of ON-052 #RBLZ260327 is unchanged. STAG expansion changes the scope of the integration, which changes the reported total. Any apparent increase upon STAG expansion should be communicated to buyers as a methodological refinement, with the old and new STAG IDs both visible on the certificate of analysis, not as a quality improvement.
Practical Implication
Treat "Total Ganoderic Acids" as a STAG-bound term and require both the STAG ID and the integrated peak list on every certificate. Two laboratories reporting different STAGs are not in disagreement; a single laboratory changing its STAG without updating the certificate name is.
STAG-USP (Narrow)
21.4%
GA-A
reported total 21.4%
STAG-A (Declared List)
23.4%
GA-A, GA-B, GA-C1, GA-C2, GA-C6, GA-D, GA-F, GA-G, GA-H, GA-J, GE-A, GE-B, GE-C, GE-D, GE-E, GE-F, GE-G, GE-H
reported total 23.4%
Same sample
Figure · Same Sample, Narrower vs Broader STAG
Native Fruiting-Body Chemistry
What a Mature Non-Extracted Fruiting Body Shows
This dried mature Reishi fruiting body was analyzed as non-extracted material to show the native acidic-triterpene chemistry in high-quality fruiting-body biomass. The result supports the choice of STAG-A analytes because these ganoderic and ganoderenic acids are present in authentic mature Reishi tissue before any extract concentration.25
0.743% Total GA native, STAG-USP
10 Analytes USP monograph (before our method update)
| Analyte | RT (min) | % |
|---|---|---|
| Ganoderenic acid C | 8.387 | 0.027 |
| Ganoderic acid C2 | 9.145 | 0.024 |
| Ganoderic acid G | 10.728 | 0.058 |
| Ganoderenic acid B | 11.698 | 0.025 |
| Ganoderic acid B | 12.662 | 0.031 |
| Ganoderic acid A (anchor) | 17.282 | 0.193 |
| Ganoderic acid H | 19.616 | 0.044 |
| Ganoderenic acid D | 21.510 | 0.133 |
| Ganoderic acid D | 23.232 | 0.095 |
| Ganoderic acid F | 26.438 | 0.112 |
| Total Ganoderic Acids (STAG-USP scope) | 0.743% |
Practical Implication
This run uses the older USP-list method that quantifies only the 10 analytes shown, so the 0.743% total reflects the USP scope, not the expanded current method. Even at that narrower scope, a mature dried fruiting body already carries a measurable acidic-triterpene fingerprint before extraction. Analyte selection should begin with compounds demonstrated in authentic fruiting-body tissue.
Comparative Species · G. Applanatum
Ganoderma applanatum: Same Method, Different Chemistry
Run on the same Method 1 as ON-052, sample MM-858 demonstrates how a different Ganoderma species shows a very different acidic triterpene profile under one method family. The total ganoderic acids value is two orders of magnitude lower than G. lucidum fruiting body extract, but the result is not a failed product, just a different species with its own chemistry. The point of the comparison is not the headline number; STAG-aware reporting preserves peak identity and ratios across species, so a buyer can tell what they are actually looking at.
0.199% P1 · Total Ganoderic Acids STAG-A scope, P1 sample
0.202% P2 · Total Ganoderic Acids STAG-A scope, P2 sample
0.200% Mean · Total Ganoderic Acids P1 / P2 mean (MM-858)
| Compound | P1 RT (min) | P1 area | P1 conc. (%) | P2 conc. (%) |
|---|---|---|---|---|
| Ganoderenic acid B | 11.554 | 5,965 | 0.036 | 0.034 |
| Ganoderenic acid D | 21.170 | 18,822 | 0.112 | 0.116 |
| Ganoderic acid D | 22.537 | 8,569 | 0.051 | 0.051 |
| Σ Total Ganoderic Acids (STAG-A) | 33,356 | 0.199% | 0.202% |
Other ganoderic and ganoderenic acid peak labels were reserved by the method (Ganoderenic acid C, Ganoderic acid C2, F, H, A, B, G) and were not quantified in this sample. They are not present at levels the active method integrates. Whether they are absent from G. applanatum in general or whether the method conditions are sub-optimal for this matrix is a question for follow-up validation. What this run does show is a clean ganoderenic-D-dominant profile, with ganoderenic D the largest peak, ganoderic D second, and ganoderenic B a minor contributor. That is a different chemistry signature than the GA-A-anchored profile typical of G. lucidum fruiting body extracts.
Why Species-Level Reporting Matters
A single "total ganoderic acids" number cannot tell a buyer whether they have G. lucidum, G. applanatum, or a blend. The peak identity and the ratios between peaks can. STAG-A, reported with the integrated peak list, preserves that information across species. ON-052 (G. lucidum) and MM-858 (G. applanatum) sit in the same STAG framework but tell two different stories.
Method PDA Ch 1 at 257 nm at 4.8 nm · Waters UPLC + Empower 3 · GA-A reference (Cayman Lot 0649826-17) · Acquired 3/4/2026; processed 3/5/2026 · Acquired by W. Christmas. Sample MM-858 #GANOAPPL021926, P1 and P2.
What a Bioactives-First Reishi Standard Looks Like in Practice
The published chemistry on Reishi already supports a multi-class, material-specific quality standard. The testing techniques are common: HPLC-DAD, UPLC-MS/MS, enzymatic glucan kits, and the ergosterol / nucleoside HPLC panels that many contract botanical labs run today. What has been missing is a labeling discipline (STAG) that makes "total" claims comparable, and a willingness to split the standard by material type instead of by single marker.
1
Anchor the standard to bioactives, not generic markers.
Method scope follows from compounds with plausible or documented biological activity. Analytical convenience is a constraint on the method, not the criterion for what to standardize.
2
Require a STAG ID for every grouped claim.
"Total ganoderic acids," "total triterpenes," and "total polysaccharides" are STAG-bound terms. The STAG ID and the integrated compound list belong on every certificate of analysis.
3
Split the standard by material type.
Four method profiles, not one. Fruiting body uses Method 1 HPLC-UV plus Method 2 UPLC-MS/MS; mycelium / full-spectrum and spore products each need their own independently validatable method profile.
4
Use validated RRFs for routine QC.
Reference standards are required for method development and validation. Routine QC can run with anchor standards (GA-A, LA-A, ergosterol, adenosine, Megazyme β-glucan) plus validated relative response factors for the rest of the panel.
5
Require linkage-specific glucan reporting.
Polysaccharide STAG = enzymatic β-(1,3/1,6)-D-glucan AND a co-reported α-D-glucan (starch) value. A single colorimetric "total polysaccharides" figure is not a STAG.
6
Run Method 2 alongside Method 1.
UPLC-MS/MS for lanostane alcohols complements the HPLC-UV acidic panel and creates a fruiting body / spore authenticity check that is difficult to fool with substrate-dilution products.
7
Communicate STAG expansion clearly.
When a STAG is broadened (by adding peaks under validated RRFs), the reported total can move upward without any change in the underlying material. Display the old and new STAG IDs side by side on the COA during any transition.
Standardize the bioactive, not the marker. Declare every total with a STAG. Split the method by material. Use anchors for routine QC. The result is a Reishi quality standard that consumers, brands, and labs read the same way, and that authentic Reishi can pass. Assay methods for bioactives are a quality marker above all else, because they are using compounds with known bioactivities tied to valid scientific research. This proposal may also inform AOAC BIDSI discussions and future method calls. A more formal, peer-reviewed review article is planned for submission to the Journal of AOAC INTERNATIONAL; this white paper is being released now to inform ongoing method discussions and working groups.
495+ Triterpenoids Characterized
6 Bioactive Classes
4 Method Profiles
About This Paper
Written and prepared by Paul Eftang for Nootropics Depot. Example assay data provided by Omnient Labs. Released as a public reference for the Reishi industry, analytical labs, and any standards body (including AOAC INTERNATIONAL's BIDSI program) developing performance requirements for Reishi testing. Statements regarding ingredient functions describe established structure-function and biochemical roles in the cited public sources. Informational only; not medical advice and not a claim to diagnose, treat, cure, or prevent any disease. Individual responses to dietary supplements vary; consumers with medical conditions or on prescription therapy should consult a qualified health professional before adding any supplement. v1.9 · 2026.
References
- Su, J. et al. A Review of Ganoderma Triterpenoids and Their Bioactivities. Biomolecules (2023). https://pmc.ncbi.nlm.nih.gov/articles/PMC9856212/
- Wang, Y. et al. A Review on the Sources, Structures, and Pharmacological Activities of Lucidenic Acids. Molecules (2023). https://pmc.ncbi.nlm.nih.gov/articles/PMC9962123/
- Ekiz, E. et al. Recent Advances in the Preparation, Structure, and Biological Activities of β-Glucan from Ganoderma Species. (2023). https://pmc.ncbi.nlm.nih.gov/articles/PMC10419088/
- Zhang, J. et al. Screening and Analysis of the Marker Components in Ganoderma lucidum by HPLC and HPLC-MSn with the Aid of Chemometrics. (2018). https://pmc.ncbi.nlm.nih.gov/articles/PMC6154496/
- Yan, Z. et al. Global Profiling Quality Assessment of Ganoderma. Frontiers in Pharmacology (2018). https://pmc.ncbi.nlm.nih.gov/articles/PMC5857333/
- Influence of cultivation substrate on antioxidant activities and triterpenoid profiles of the fruiting body of Ganoderma lucidum. (2024). https://pmc.ncbi.nlm.nih.gov/articles/PMC10879320/
- Da, J. et al. An Improved HPLC-DAD Method for Quantitative Comparisons of Triterpenes in Ganoderma lucidum. Molecules (2015). https://www.mdpi.com/1420-3049/20/1/1059/pdf
- Mycelial triterpenoid HPLC profiles. (2023). https://www.mdpi.com/2036-7481/14/3/92/pdf?version=1694683815
- Spore Triterpenoid Review. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC3271404/
- Pharmacokinetic comparison of triterpenoids in Ganoderma lucidum spore powder by UPLC-QqQ-MS. Biomedical Chromatography (2024). https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/bmc.5787
- Sharma, C. et al. Bioactivities and industrial standardization status of Ganoderma lucidum: A comprehensive review. Heliyon (2024). 10(19):e36987. https://doi.org/10.1016/j.heliyon.2024.e36987
- AOAC INTERNATIONAL. Call for Reishi Working Group. https://www.aoac.org/news/call-for-reishi-working-group/
- AOAC INTERNATIONAL. BIDSI Program 2-Pager (2025). https://www.aoac.org/wp-content/uploads/2025/02/2025-BIDSI-2-Pager-FINAL.pdf
- Omnient Labs. ON-052 Reishi Mushroom Extract #RBLZ260327 Report 4 (2026). Internal method-development report.
- Omnient Labs. MM-858 Ganoderma Applanatum #GANOAPPL021926 Report (2026). Internal method-development report.
- Nootropics Depot. Red Reishi Mushroom Capsules (9% Ganoderic Acids). https://nootropicsdepot.com/red-reishi-mushroom-ultra-concentrated-extract-capsules-9/
- Nootropics Depot. LucidiMax Capsules (Optimized Reishi). https://nootropicsdepot.com/lucidimax-capsules/
- Nootropics Depot. LucidiSPORE Supercritical CO2 Reishi Spore Oil. https://nootropicsdepot.com/lucidispore-super-critical-co2-reishi-spore-oil/
- Withania somnifera tolerability and withanolide diversity (40+ withanolides characterized). PMC (2024). https://pmc.ncbi.nlm.nih.gov/articles/PMC12741928/
- USP. Powdered Ashwagandha Root Extract monograph (root scope). https://www.drugfuture.com/pharmacopoeia/usp35/data/v35300/usp35nf30s0_m2789.html
- NIH Office of Dietary Supplements. Ashwagandha fact sheet (root vs leaf composition). https://ods.od.nih.gov/factsheets/Ashwagandha-HealthProfessional/
- Kaewnarin, K. et al. High-Resolution QTOF-MRM for Highly Accurate Identification and Quantification of Trace Levels of Triterpenoids in Ganoderma lucidum Mycelium. J. Am. Soc. Mass Spectrom. (2021). https://pubs.acs.org/doi/10.1021/jasms.1c00175
- ICH Q2(R2). Validation of Analytical Procedures. ICH Harmonised Guideline (2023). https://database.ich.org/sites/default/files/ICH_Q2-R2_Document_Step4_Guideline_2023_1130.pdf
- Omnient Labs. Reishi Triterpenoid Peak Identification, SSF-2913 / BLK1416 / LG90450325. Internal method-development table and chromatogram, 2026.
- Omnient Labs. MM-717 Mature Reishi Mushroom P2 10x analytical report and fruiting-body specimen photographs (2026). Internal method-development record.
This content is for informational purposes only and is not intended as medical advice. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Always consult a healthcare professional before starting any new supplement.